Case Report: Metastatic colorectal cancer with ALK-CEP44 fusion and rapid resistance development [0.03%]
病例报告：ALK-CEP44融合阳性转移性结直肠癌及快速耐药问题
Silvan Hofmann,Claudine Egger,Silke Potthast et al.
Silvan Hofmann et al.
Background: Colorectal cancer rarely harbors rearrangements in the ALK gene, and the therapeutic significance of non-canonical or functionally unclear ALK fusions remains poorly defined. We report a case of metastatic CRC...
Cardiovascular adverse effects of immunotherapy in cancer: insights and implications [0.03%]
免疫治疗在癌症中的心血管不良反应：见解和启示
Haiping Du,Jie Wang,Zhen Wang
Haiping Du
Immunotherapy has revolutionized cancer treatment, offering novel therapeutic strategies such as immune checkpoint inhibitors (ICIs), chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines. However, these modalities are associa...
Development of a model to predict Ki-67 expression status in non-Hodgkin's lymphoma based on PET radiomics [0.03%]
基于PET影像组学的非霍奇金淋巴瘤Ki-67表达状态预测模型的研究
Ke Tian,Pengfei Tong,Keliu Wu et al.
Ke Tian et al.
Introduction: This study aims to evaluate the effectiveness of conventional metabolic parameters and radiomic features from 18F-deoxyglucose(FDG) PET in predicting Ki-67 expression status in patients with non-Hodgkin's ly...
The efficacy and safety of intrathecal pemetrexed for leptomeningeal metastasis from non-small cell lung cancer: a single-arm meta-analysis of Chinese patients [0.03%]
培美曲塞鞘内注射治疗非小细胞肺癌患者脑膜转移的疗效和安全性：中国患者的单组Meta分析
Yushi Zhao,Xueqin Gao,Yong Han et al.
Yushi Zhao et al.
Objectives: The purpose of this meta-analysis is to evaluate the safety and effectiveness of intrathecal pemetrexed (IP) in patients with non-small cell lung cancer with leptomeningeal metastasis (NSCLC-LM). ...
High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab [0.03%]
墨西哥高危型神经母细胞瘤治疗：从多模式方法到免疫疗法。首例naxitamab治疗病例报告
Alberto Olaya Vargas,Haydee Salazar-Rosales,Marcela Caballero-Palacios et al.
Alberto Olaya Vargas et al.
Introduction: We report herein the case of a patient diagnosed with high-risk neuroblastoma (HR-NB), treated with naxitamab following suboptimal response to induction chemotherapy, becoming the first patient to receive th...
The anti-inflammatory effects of oridonin in resisting esophageal cancer [0.03%]
oriadenum的抗炎效应抵抗食道癌
Mengfan Peng,Xiaofang Zhang,Lei Yang et al.
Mengfan Peng et al.
Objectives: Explore whether Oridonin (Ori) improves esophageal cancer by interfering in the TLR4/NF-κB/NLRP3 inflammasome. Materials and methods: ...
Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: results of a nurse survey [0.03%]
一种体内递送系统在多发性骨髓瘤患者皮下注射伊沙妥昔单抗中的应用：护士调研结果
Nuria Sánchez Avello,Paula Calvo Pajares,Paul Cordero et al.
Nuria Sánchez Avello et al.
Introduction: Subcutaneous (SC) administration of the anti-CD38 antibody isatuximab (Isa) by an on-body delivery system (OBDS), plus pomalidomide-dexamethasone, has demonstrated safety and efficacy comparable to intraveno...
Clinical utility of self-expandable metal stents in the treatment of anastomotic obstruction secondary to recurrent gastric cancer [0.03%]
自扩式金属支架治疗胃癌复发后吻合口狭窄的临床应用价值研究
Haiyang Lai,Ketong Wu,Yang Liu et al.
Haiyang Lai et al.
Aim: The purpose of this study was to assess the efficacy and safety of self-expandable metal stents (SEMS) in treating anastomotic obstruction associated with recurrent gastric cancer. ...
Deciphering the impact of intra-tumoral bacterial infiltration on multi-omics profiles in low-grade gliomas [0.03%]
解码肿瘤内细菌浸润对低级别胶质瘤多组学特征的影响
Wenshu Li,Zixiang Zhu,Longyuan Li et al.
Wenshu Li et al.
Background: Low-grade gliomas (LGGs) exhibit diverse bacterial infiltrations. This study delves into the intricate relationship between microbial infiltration in glioma samples and tumor multi-omics characteristics, aimin...
Patient-reported symptoms in the detection of head and neck cancer recurrence: a systematic review [0.03%]
头颈部癌症复发的患者报告症状的系统评价
Kate Hulse,Rhona Hurley,Anja Lowit et al.
Kate Hulse et al.
Introduction: Patient-initiated follow-up (PIFU) after treatment for head and neck cancer (HNC) relies on the signs and symptoms of recurrence being detectable by patients. We examine the evidence for patient-reported sym...